Particle therapy fights with a prescribed high load and extreme precision against radioresistant tumors, while preserving healthy tissue.
2031. Catherine has a chronic illness. AI and digital interventions shape her care through diagnosis, psychological support, therapeutic guidance, and medication.
When physicians present to a colleague as a patient, should they disclose their profession? Are there subjective preferences, or an ethical duty to do so?
APAAACI´s recent white paper showed that various air pollutants threaten human respiratory and cardiovascular health
The APAAACI Task Force on COVID-19 recognized most common atopic conditions and skin allergies in healthcare workers during the pandemic.
Young physicians in Brazil and Ireland are struggling with anxiety disorder even months after working in clinical practice during the pandemic.
During pregnancy, women are not only at high risk for severe progression of the disease, they also face an increased risk of premature births and stillbirths.
In pathology, the protein Ki-67 is used to analyse conspicuous tissue changes. Researchers have discovered how this helpful protein is formed.
Compelling evidence suggests that many MS cases could be prevented by stopping EBV infection.
rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.
The final trial results showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.
The large, population-based study showed prevalence in 40 years+ patients. Approximately 1 out of 3 smouldering MM patients may progress towards MM.
Fitusiran prophylactic therapy reduced the ABR in severe haemophilia A or B patients without inhibitors. Quality of life increase was associated with fitusiran therapy.
Teclistamab was safe and efficacious in relapsed/refractory multiple myeloma patients. Phase 1/2 trial showed durable and deepening responses.
Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.
CHIP was related to decreased risk of AD and its neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.
Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.
A quizartinib, venetoclax and decitabine combo was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia.
Cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in newly diagnosed AML patients.
The 5-azacitidine, venetoclax, and magrolimab combo had good response rates in newly diagnosed older, unfit, or TP53-mutated AML patients.